Dapibus™ Protein Production Platform

Dyadic International, Inc. (NASDAQ: DYAI)

We are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based

Dyadic’s newly developed Dapibus™ filamentous fungal based microbial protein production platform is reenginnered to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.

The current focus for the Dapibus™ platform is in our Alternative Proteins business segment.  Given the Dyadic’s industrial heritage, the expertise to rapidly achieve commercial scale within margin sensitive markets such as food and nutrition enzymes, provides our partners with the ability to move from demonstration to commercial production quickly and efficiently.


Current Market Opportunities

Food and Nutrition

  • Current projects in cell culture media, enzymes, and growth factors to enable commercial scale production or reduce costs in both plant and lab-grown meat segments.

Reagent-Research Grade Materials

  • Internal projects directed at lowering the costs of research and product development through production of high-quality and affordable recombinant proteins and enzymes at different grades.